Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak ( for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 20, Number 2, 2015

Influence of 11C-choline PET/CT on radiotherapy planning in prostate cancer

Escarlata López, Antonio Lazo, Antonio Gutiérrez, Gregorio Arregui, Isabel Núñez, Antonio Sacchetti



To evaluate the influence of 11C-choline PET/CT on radiotherapy planning in prostate cancer patients.


Precise information on the extension of prostate cancer is crucial for the choice of an appropriate therapeutic strategy.

11C-choline positron emission tomography (11C-choline PET/CT) has two roles in radiation oncology (RT): (1) patient selection for treatment and (2) target volume selection and delineation.

In conjunction with high-accuracy techniques, it might offer an opportunity of dose escalation and better tumour control while sparing healthy tissues.

Materials and methods

We carried out a retrospective study in order to analyse RT planning modification based on 11C-choline PET/CT in 16 prostate cancer patients. Patients were treated with hypofractionated step-and-shoot Intensity Modulated Radiotherapy (IMRT), or Volumetric Modulated Arc Therapy (VMAT), and a daily cone-beam CT for Image Guided Radiation Therapy (IGRT). All patients underwent a 11C-choline-PET/CT scan prior to radiotherapy.


In 37.5% of cases, a re-delineation and new dose prescription occurred. Data show good preliminary clinical results in terms of biochemical control and toxicity. No gastrointestinal (GI)/genitourinary (GU) grade III toxicities were observed after a median follow-up of 9.5 months.


In our experience, concerning the treatment of prostate cancer (PCa), 11C-choline PET/CT may be helpful in radiotherapy planning, either for dose escalation or exclusion of selected sites.

Signature: Rep Pract Oncol Radiother, 2015; 20(2) : 104-112

« back


Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.